Treatment of Stenotrophomonas maltophilia infections comprises of sulfamethoxazole/tripethoprim (SXT) or fluoroquinolones. We investigated antimicrobial resistance, presence of resistance genes (sul1, smqnr) and clonal dissemination in S. maltophilia from a university hospital. Among 62 isolates, 45 (73%) represented infection. Two isolates (3%) were resistant to SXT and three (5%) to levofloxacin. Twenty-nine isolates (47%), including two out of three levofloxacin-resistant, carried smqnr. Resistance of S. maltophilia was low and was not associated with sul1 or smqnr carriage. Although high degree of genetic diversity was identified (29 pulsotypes), 22/62 (35.5%) strains were classified into four clones; clone b was associated with bacteraemias.
Citation: Matthaios Papadimitriou-Olivgeris, Fevronia Kolonitsiou, Maria Militsopoulou, Iris Spiliopoulou, Nikolaos Giormezis. Clonal dissemination and resistance genes among Stenotrophomonas maltophilia in a Greek University Hospital during a four-year period[J]. AIMS Microbiology, 2022, 8(3): 292-299. doi: 10.3934/microbiol.2022021
Treatment of Stenotrophomonas maltophilia infections comprises of sulfamethoxazole/tripethoprim (SXT) or fluoroquinolones. We investigated antimicrobial resistance, presence of resistance genes (sul1, smqnr) and clonal dissemination in S. maltophilia from a university hospital. Among 62 isolates, 45 (73%) represented infection. Two isolates (3%) were resistant to SXT and three (5%) to levofloxacin. Twenty-nine isolates (47%), including two out of three levofloxacin-resistant, carried smqnr. Resistance of S. maltophilia was low and was not associated with sul1 or smqnr carriage. Although high degree of genetic diversity was identified (29 pulsotypes), 22/62 (35.5%) strains were classified into four clones; clone b was associated with bacteraemias.
| [1] |
Brooke JS (2012) Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev 25: 2-41. https://doi.org/10.1128/CMR.00019-11 
|
| [2] | Lai CH, Chi CY, Chen HP, et al. (2004) Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 37: 350-358. Available from: https://pubmed.ncbi.nlm.nih.gov/15599467/ |
| [3] |
Chang LL, Chen HF, Chang CY, et al. (2004) Contribution of integrons, and SmeABC and SmeDEF efflux pumps to multidrug resistance in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 53: 518-521. https://doi.org/10.1093/jac/dkh094
|
| [4] |
Hu LF, Chang X, Ye Y, et al. (2011) Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents 37: 230-234. https://doi.org/10.1016/j.ijantimicag.2010.10.025
|
| [5] | Malekan M, Tabaraie B, Akhoundtabar L, et al. (2017) Distribution of class I integron and smqnr resistance gene among stenotrophomonas maltophilia isolated from clinical samples in Iran. Avicenna J Med Biotechnol 9: 138-141. Available from: https://pubmed.ncbi.nlm.nih.gov/28706609/ |
| [6] | (2020) Clinical and Laboratory Standards InstitutePerformance standards for antimicrobial susceptibility testing. CLSI supplement M100. PA: Wayne. Available from: https://www.clsi.org/standards/products/microbiology/documents/m100/ |
| [7] |
Bostanghadiri N, Ghalavand Z, Fallah F, et al. (2019) Characterization of phenotypic and genotypic diversity of Stenotrophomonas maltophilia strains isolated from selected hospitals in Iran. Front Microbiol 10: 1191. https://doi.org/10.3389/fmicb.2019.01191
|
| [8] |
Tenover FC, Arbeit RD, Goering RV, et al. (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33: 2233-2239. https://doi.org/10.1128/jcm.33.9.2233-2239.1995
|
| [9] |
Neela V, Rankouhi SZ, van Belkum A, et al. (2012) Stenotrophomonas maltophilia in Malaysia: molecular epidemiology and trimethoprim-sulfamethoxazole resistance. Int J Infect Dis 16: e603-e607. https://doi.org/10.1016/j.ijid.2012.04.004
|
| [10] | Song JH, Sung JY, Kwon KC, et al. (2010) Analysis of acquired resistance genes in Stenotrophomonas maltophilia. Korean J Lab Med 30: 295-300. https://doi.org/10.3343/kjlm.2010.30.3.295 |
| [11] |
Hu LF, Chen GS, Kong QX, et al. (2016) Increase in the prevalence of resistance determinants to trimethoprim/sulfamethoxazole in clinical Stenotrophomonas maltophilia isolates in China. PloS One 11: e0157693. https://doi.org/10.1371/journal.pone.0157693
|
| [12] |
Kanamori H, Yano H, Tanouchi A, et al. (2015) Prevalence of smqnr and plasmid-mediated quinolone resistance determinants in clinical isolates of Stenotrophomonas maltophilia from Japan: novel variants of Smqnr. New Microbes New Infect 7: 8-14. https://doi.org/10.1016/j.nmni.2015.04.009
|
| [13] |
Juhász E, Krizsán G, Lengyel G, et al. (2014) Infection and colonization by Stenotrophomonas maltophilia: antimicrobial susceptibility and clinical background of strains isolated at a tertiary care centre in Hungary. Ann Clin Microbiol Antimicrob 13: 333. https://doi.org/10.1186/s12941-014-0058-9
|
| [14] | Ebrahim-Saraie HS, Heidari H, Soltani B, et al. (2019) Prevalence of antibiotic resistance and integrons, sul and Smqnr genes in clinical isolates of Stenotrophomonas maltophilia from a tertiary care hospital in Southwest Iran. Iran J Basic Med Sc 22: 872-877. https://doi.org/10.22038/ijbms.2019.31291.7540 |
| [15] |
Kaur P, Gautam V, Tewari R (2015) Distribution of class 1 integrons, sul1 and sul2 genes among clinical isolates of Stenotrophomonas maltophilia from a tertiary care hospital in North India. Microbial drug resistance (Larchmont,N.Y.) 21: 380-385. https://doi.org/10.1089/mdr.2014.0176
|
| [16] |
Kolonitsiou F, Papadimitriou-Olivgeris M, Spiliopoulou A, et al. (2017) Trends of bloodstream infections in a university greek hospital during a three-year period: Incidence of multidrug-resistant bacteria and seasonality in gram-negativep Predominance. Pol J Microbiol 66: 171-180. https://doi.org/10.5604/01.3001.0010.7834
|
| [17] | European Centre for Disease Prevention and ControlPoint prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals (2013). https://doi.org/10.2807/ese.17.46.20316-en |
| [18] |
Valdezate S, Vindel A, Martín-Dávila P, et al. (2004) High genetic diversity among Stenotrophomonas maltophilia strains despite their originating at a single hospital. J Clin Microbiol 42: 693-699. https://doi.org/10.1128/JCM.42.2.693-699.2003
|
| [19] | Wang N, Tang C, Wang L (2022) Risk factors for acquired Stenotrophomonas maltophilia pneumonia in intensive care unit: A systematic review and meta-analysis. Front Med 8: 808391. https://doi.org/10.3389/fmed.2021.808391 |
| [20] |
Lin Q, Zou H, Chen X, et al. (2021) Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro. BMC Microbiol 21: 60. https://doi.org/10.1186/s12866-021-02108-2
|
Figures(1) / Tables(2)
Matthaios Papadimitriou-Olivgeris, Fevronia Kolonitsiou, Maria Militsopoulou, Iris Spiliopoulou, Nikolaos Giormezis. Clonal dissemination and resistance genes among Stenotrophomonas maltophilia in a Greek University Hospital during a four-year period[J]. AIMS Microbiology, 2022, 8(3): 292-299. doi: 10.3934/microbiol.2022021
DownLoad: